{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T06:04:59Z","timestamp":1778220299502,"version":"3.51.4"},"reference-count":43,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"am","delay-in-days":348,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","redjournal.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ijrobp.2025.01.033","type":"journal-article","created":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T23:15:06Z","timestamp":1739056506000},"page":"424-434","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Intracranial Disease Control and Survival among Patients with KRAS-mutant Lung Adenocarcinoma and Brain Metastases Treated with Stereotactic Radiosurgery"],"prefix":"10.1016","volume":"122","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2830-5864","authenticated-orcid":false,"given":"Benjamin","family":"Gaeta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordan E.","family":"Eichholz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry","family":"Walch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmet T.","family":"Ilica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lillian","family":"Boe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leah","family":"Kratochvil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel R.","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brandon S.","family":"Imber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bob T.","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yonina R.","family":"Murciano-Goroff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn C.","family":"Arbour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaus","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily S.","family":"Lebow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9622-7442","authenticated-orcid":false,"given":"Luke R.G.","family":"Pike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2025.01.033_bib0001","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/ijc.31937","article-title":"Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods","volume":"144","author":"Ferlay","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ijrobp.2025.01.033_bib0002","doi-asserted-by":"crossref","first-page":"8","DOI":"10.5334\/aogh.2419","article-title":"Global epidemiology of lung cancer","volume":"85","author":"Barta","year":"2019","journal-title":"Ann Glob Health"},{"key":"10.1016\/j.ijrobp.2025.01.033_bib0003","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41582-020-0391-x","article-title":"Management of brain metastases according to molecular subtypes","volume":"16","author":"Soffietti","year":"2020","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.ijrobp.2025.01.033_bib0004","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.nec.2020.06.001","article-title":"Epidemiology of brain metastases","volume":"31","author":"Sacks","year":"2020","journal-title":"Neurosurg Clin N Am"},{"key":"10.1016\/j.ijrobp.2025.01.033_bib0005","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature13385","article-title":"Comprehensive molecular profiling of lung adenocarcinoma","volume":"511","author":"Collisson","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ijrobp.2025.01.033_bib0006","article-title":"KRAS mutation as a prognostic factor and predictive factor in advanced\/metastatic non-small cell lung cancer: A systematic literature review and meta-analysis","volume":"24","author":"Goulding","year":"2020","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.ijrobp.2025.01.033_bib0007","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.7314\/APJCP.2015.16.10.4439","article-title":"KRAS mutation as a biomarker for survival in patients with non-small cell lung cancer, a meta-analysis of 12 randomized trials","volume":"16","author":"Ying","year":"2015","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.ijrobp.2025.01.033_bib0008","doi-asserted-by":"crossref","first-page":"8373","DOI":"10.18632\/oncotarget.7080","article-title":"KRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: A meta-analysis of 41 studies","volume":"7","author":"Pan","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ijrobp.2025.01.033_bib45","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","article-title":"Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology","volume":"17","author":"Cheng","year":"2015","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.ijrobp.2025.01.033_bib0013","doi-asserted-by":"crossref","first-page":"5911","DOI":"10.1038\/sj.onc.1210418","article-title":"Prevalence and specificity of LKB1 genetic alterations in lung cancers","volume":"26","author":"Matsumoto","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.ijrobp.2025.01.033_bib0014","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.jtho.2022.03.011","article-title":"KEAP1-mutant NSCLC: The catastrophic failure of a cell-protecting hub","volume":"17","author":"Scalera","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.033_bib0011","doi-asserted-by":"crossref","first-page":"5701","DOI":"10.1158\/1078-0432.CCR-20-1825","article-title":"The genomic landscape of SMARCA4 alterations and associations with outcomes in patients with lung cancer","volume":"26","author":"Schoenfeld","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2025.01.033_bib0009","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1158\/2159-8290.CD-14-1236","article-title":"Co-occurring genomic alterations define major subsets of kras-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities","volume":"5","author":"Skoulidis","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ijrobp.2025.01.033_bib0015","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1158\/1078-0432.CCR-17-1841","article-title":"Effects of co-occurring genomic alterations on outcomes in patients with KRAS-mutant non-small cell lung cancer","volume":"24","author":"Arbour","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2025.01.033_bib0016","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.102","article-title":"Association of STK11\/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer","volume":"37","author":"Skoulidis","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.033_bib0017","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ejca.2021.08.011","article-title":"STK11\/LKB1 and KEAP1 mutations in non-small cell lung cancer: Prognostic rather than predictive?","volume":"157","author":"Di Federico","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijrobp.2025.01.033_bib0018","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1200\/JCO.2017.75.3384","volume":"36","author":"Rizvi","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.033_bib0019","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2204619","article-title":"Adagrasib in non\u2013small-cell lung cancer harboring a KRASG12C mutation","volume":"387","author":"J\u00e4nne","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2025.01.033_bib0020","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for lung cancers with KRAS p.G12C mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2025.01.033_bib0021","article-title":"Clinical and genomic features of response and toxicity to sotorasib in a real-world cohort of patients with advanced KRAS G12C-mutant non\u2013small cell lung cancer","volume":"7","author":"Thummalapalli","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.033_bib0022","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1158\/2159-8290.CD-22-1420","article-title":"Comutations and KRASG12C inhibitor efficacy in advanced NSCLC","volume":"13","author":"Negrao","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ijrobp.2025.01.033_bib0023","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non\u2013small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2025.01.033_bib0024","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non\u2013small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2025.01.033_bib0025","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2025.01.033_bib0026","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.lungcan.2017.12.008","article-title":"Intracerebral efficacy and tolerance of nivolumab in non\u2013small-cell lung cancer patients with brain metastases","volume":"116","author":"Gauvain","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ijrobp.2025.01.033_bib0027","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S1470-2045(20)30111-X","article-title":"Pembrolizumab for management of patients with NSCLC and brain metastases: Long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial","volume":"21","author":"Goldberg","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.033_bib0028","doi-asserted-by":"crossref","first-page":"4478","DOI":"10.1200\/JCO.22.02561","article-title":"Phase II trial of atezolizumab combined with carboplatin and pemetrexed for patients with advanced nonsquamous non\u2013small-cell lung cancer with untreated brain metastases (Atezo-Brain, GECP17\/05)","volume":"41","author":"Nadal","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.033_bib0029","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/s41571-022-00676-4","article-title":"The KRYSTAL-1 study of adagrasib \u2014 a new trial for KRASG12C-mutated non-small-cell lung cancer","volume":"19","author":"Murciano-Goroff","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.033_bib0030","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(22)00271-6","article-title":"Stereotactic radiosurgery versus whole brain radiotherapy in patients with intracranial metastatic disease and small-cell lung cancer: A systematic review and meta-analysis","volume":"23","author":"Gaebe","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.033_bib0031","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S1470-2045(09)70263-3","article-title":"Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: A randomised controlled trial","volume":"10","author":"Chang","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.033_bib0032","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1016\/S1470-2045(15)70057-4","article-title":"Response assessment criteria for brain metastases: Proposal from the RANO group","volume":"16","author":"Lin","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.033_bib0033","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/JTO.0000000000000432","article-title":"Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas","volume":"10","author":"Yu","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.033_bib0034","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1158\/1078-0432.CCR-20-4023","article-title":"Treatment outcomes and clinical characteristics of patients with KRAS-G12C-mutant non-small cell lung cancer","volume":"27","author":"Arbour","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2025.01.033_bib0035","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.lungcan.2020.06.030","article-title":"Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer","volume":"146","author":"Cui","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ijrobp.2025.01.033_bib0036","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1186\/s12885-023-10778-6","article-title":"Overall survival in patients with advanced non-small cell lung cancer with KRAS G12C mutation with or without STK11 and\/or KEAP1 mutations in a real-world setting","volume":"23","author":"Julian","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ijrobp.2025.01.033_bib0037","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1016\/j.annonc.2020.08.2105","article-title":"KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden","volume":"31","author":"Marinelli","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.033_bib0038","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ijrobp.2025.01.033_bib0039","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1093\/neuonc\/nou146","article-title":"Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases","volume":"17","author":"Mak","year":"2015","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.ijrobp.2025.01.033_bib0040","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.3390\/ijms17122132","article-title":"EGFR and KRAS mutations predict the incidence and outcome of brain metastases in non-small cell lung cancer","volume":"17","author":"Tomasini","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ijrobp.2025.01.033_bib0041","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.ijrobp.2009.08.025","article-title":"Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: A multi-institutional analysis of 4,259 patients","volume":"77","author":"Sperduto","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.01.033_bib0042","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s00262-021-03031-1","article-title":"Anti-PD-(L)1 for KRAS-mutant advanced non-small-cell lung cancers: a meta-analysis of randomized-controlled trials","volume":"71","author":"Landre","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ijrobp.2025.01.033_bib0043","doi-asserted-by":"crossref","DOI":"10.1177\/11795549221092747","article-title":"Expression and prognostic significance of c-Myc, ALK, ROS1, BRAF, and PD-L1 among patients with non-small cell lung cancer","volume":"16","author":"Sunpaweravong","year":"2022","journal-title":"Clin Med Insights Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.033_bib0044","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1007\/s00432-019-03025-8","article-title":"Expression and clinical significance of PD-L1 and c-Myc in non-small cell lung cancer","volume":"145","author":"Zhou","year":"2019","journal-title":"J Cancer Res Clin Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625000938?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625000938?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T09:11:24Z","timestamp":1747300284000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301625000938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0360301625000938"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.01.033","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intracranial Disease Control and Survival among Patients with KRAS-mutant Lung Adenocarcinoma and Brain Metastases Treated with Stereotactic Radiosurgery","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.01.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}